L-dopa in uremic patients with the restless legs syndrome

Reuven Sandyk, Charles Bernick, Stanley M. Lee, Lawrence Z. Stern, Robert P. Iacono, Colin R. Bamford

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Restless legs syndrome (RLS) is a poorly understood, often distressing condition that is particularly prevalent among patients with chronic renal failure. A wide variety of medications have been used to treat RLS with variable results. In order to evaluate the efficacy of carbidopa/levodopa therapy, eight consecutive uremic patients with RLS on maintenance hemodialysis were treated with doses ranging from 25/100 to 25/250 twice daily. Six of eight patients obtained satisfactory relief which has continued for 3 months follow-up. Carbidopa/levodopa appears to be an effective option in management of RLS in patients with chronic renal failure.

Original languageEnglish (US)
Pages (from-to)233-235
Number of pages3
JournalInternational Journal of Neuroscience
Issue number3-4
StatePublished - 1987


  • Chronic renal failure
  • L-dopa
  • Restless legs syndrome

ASJC Scopus subject areas

  • Neuroscience(all)


Dive into the research topics of 'L-dopa in uremic patients with the restless legs syndrome'. Together they form a unique fingerprint.

Cite this